US Greenlights First GLP-1 Tablet for Weight Management
Novo Nordisk, the Danish pharmaceutical company, announced Monday that the US Food and Drug Administration (FDA) has given the go-ahead for its well-known GLP-1 anti-obesity medication, Wegovy, to be available as a pill for weight management.
Mike Doustdar, president and CEO of Novo Nordisk, stated that with the FDA's approval of the Wegovy pill, individuals now have access to a convenient, once-daily oral medication. This pill can help them achieve similar weight loss results as the original Wegovy injection.
While the FDA had previously approved a pill for diabetes treatment, this latest development broadens the treatment's availability. Doctors can now prescribe it for weight loss in adult patients who are obese or overweight and have at least one comorbidity linked to their weight, such as a heart ailment, according to the company.
The US Obesity Care Advocacy Network (OCAN), a non-profit advocacy organization supporting adults facing obesity, expressed its support for the news.
According to the group's statement to AFP, this advancement presents a significant opportunity for individuals managing obesity. It offers an alternative for those who may be hesitant to start injectable treatments and potentially offers a more affordable option.
The US Centers for Disease Control and Prevention (CDC) estimates that approximately 40 percent of American adults are affected by obesity.
A Significant Advancement
The popularity of the new class of appetite-suppressing drugs using GLP-1 agonists, including brands like Ozempic, Wegovy, and Mounjaro, has surged in recent years, largely due to their effectiveness in aiding weight loss. Health tracking apps like Shotlee can help monitor progress and adherence to treatment plans.
